Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study

Bone Marrow Transplantation volume 39, pages 115–120 (2007)Cite this article

Abstract

In vivo and in vitro studies suggest human growth hormone (hGH) receptors on bone marrow stem cells may be biologically active and could be exploited to promote haemopoetic recovery after intensive chemotherapy. Patients with haematological malignancies receiving intensive chemotherapy and requiring hospitalization were randomized in a double-blind, placebo-controlled single-centre trial. Patients were randomly assigned to receive either hGH 500 μg/day or placebo, for 6 weeks. There was no significant difference in patient characteristics at baseline between the placebo and treatment arms. Patients treated with hGH showed significantly faster recovery of platelets to 25 × 109/l (median of 16 versus 19 days; P=0.03) compared to the placebo-controlled arm (hazard ratio 1.47 favouring hGH, 95% confidence interval (CI), 1.03–2.08). Time to relapse did not differ significantly between arms. There was no change in the anthropometric parameters at the start and end of hGH/placebo therapy. The study drug was well tolerated. Treatment with hGH in physiological doses improves platelet recovery, but is not associated with a lower relapse rate or improved anthropometric parameters in patients receiving intensive chemotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Golde DW, Bersch N, Li CH . Growth hormone: species-specific stimulation of erythropoiesis in vitro. Science 1977; 196: 1112–1113.

    Article  CAS  Google Scholar 

  2. Merchav S, Tatarsky I, Hochberg Z . Enhancement of erythropoiesis in vitro by human growth hormone is mediated by insulin-like growth factor I. Br J Haematol 1988; 70: 267–271.

    Article  CAS  Google Scholar 

  3. Murphy WJ, Tsarfaty G, Longo DL . Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine. Blood 1992; 80: 1443–1447.

    CAS  PubMed  Google Scholar 

  4. Tian ZG, Woody MA, Sun R, Welniak LA, Raziuddin A, Funakoshi S et al. Recombinant human growth hormone promotes hematopoietic reconstitution after syngeneic bone marrow transplantation in mice. Stem Cells 1998; 16: 193–199.

    Article  CAS  Google Scholar 

  5. Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization collection of CD34+ cells in poor mobilizers. Blood 2004; 103: 3287–3295.

    Article  CAS  Google Scholar 

  6. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996; 125: 873–882.

    Article  CAS  Google Scholar 

  7. Waters D, Danska J, Hardy K, Koster F, Qualls C, Nickell D et al. Recombinant human growth hormone, insulin-like growth factor I and combination therapy in AIDS associated wasting: a randomised double-blind placebo-controlled trial. Ann Intern Med 1996; 125: 865–872.

    Article  CAS  Google Scholar 

  8. Paton N, Newton P, Sharpstone D, Ross HM, Cotton J, Calder AG et al. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive people. AIDS 1999; 13: 195–202.

    Article  Google Scholar 

  9. Cherbonnier C, Déas O, Carvalho G, Vassal G, Durrbach A, Haeffner A et al. Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-κB activity. Br J Cancer 2003; 89: 1108–1115.

    Article  CAS  Google Scholar 

  10. Lerebours E, Tilly H, Rimbert A, Delarue J, Piguet H, Colin R . Changes in energy and protein status during chemotherapy in patients with acute leukaemia. Cancer 1988; 61: 2412–2417.

    Article  CAS  Google Scholar 

  11. Couto-Silva AC, Trivin C, Esperou H, Michon J, Fischer A, Brauner R . Changes in height, weight and plasma leptin after bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1205–1210.

    Article  CAS  Google Scholar 

  12. Osoba D, Murray N, Gelmon K, Karsai H, Knowling M, Shah A et al. Quality of life, appetite and weight change in patients receiving dose-intensive chemotherapy. Oncology (Williston Park) 1994; 8: 61–65.

    CAS  Google Scholar 

  13. Kumar R, Marwaha RK, Bhalla AK, Gulati M . Protein energy malnutrition and skeletal muscle wasting in childhood acute lymphoblastic leukaemia. Indian Paediatr 2000; 37: 720–726.

    CAS  Google Scholar 

  14. Mehta J, Powles R, Treleaven J, Swansbury GJ, Kulkarni S, Saso R et al. The impact of karyotyping on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy. Leuk Lymph 1999; 34: 553–560.

    Article  CAS  Google Scholar 

  15. Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003; 102: 4277–4283.

    Article  CAS  Google Scholar 

  16. Powles R, Sirohi B, Treleaven J, Kulkarni S, Tait D, Singhal S et al. The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukaemia. Blood 2002; 100: 1641–1647.

    Article  CAS  Google Scholar 

  17. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G et al. Increased mortality associated with growth hormone treatment in critically ill adults. Ne Engl J Med 1999; 341: 785–792.

    Article  CAS  Google Scholar 

  18. Laursen T, Møller J, Jorgensen JO, Orskov H, Christiansen JS . Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients. Clin Endocrin 1996; 45: 333–339.

    Article  CAS  Google Scholar 

  19. Bentham J, Rodriguez-Arnao J, Ross RJ . Acquired growth hormone resistance in patients with hypercatabolism. Horm Res 1993; 40: 87–91.

    Article  CAS  Google Scholar 

  20. Timmins AC, Cotterill AM, Hughes SC, Holly JM, Ross RJ, Blum W et al. Critical illness is associated with low circulating concentration of insulin-like growth factors-I and -II. Alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med 1996; 24: 1460–1466.

    Article  CAS  Google Scholar 

  21. Ge NL, Rudikoff S . Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 2856–2861.

    CAS  PubMed  Google Scholar 

  22. Gilden D . Human growth hormone available for AIDS wasting. GMHC Treat Issues 1995; 9: 9–11.

    PubMed  Google Scholar 

  23. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M . Insulin-like growth factor (IGF-1), IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346–1353.

    Article  CAS  Google Scholar 

  24. Swerdlow AJ, Higgins CD, Adlard P, Preece MA . Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet 2002; 360: 273–277.

    Article  CAS  Google Scholar 

  25. Fiebig HH, Dengler W, Hendricks HR . No evidence of tumour growth stimulation in human tumours in vitro following treatment with recombinant human growth hormone. Anticancer Drugs 2000; 11: 659–664.

    Article  CAS  Google Scholar 

  26. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 2002; 87: 3136–3141.

    Article  CAS  Google Scholar 

  27. Cherbonnier C, Deas O, Vassal G, Merlin JL, Haeffner A, Senik A et al. Human growth hormone gene transfer into tumor cells may improve cancer chemotherapy. Cancer Gene Ther 2002; 9: 497–504.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haemato-Oncology Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK

    B Sirohi, R Powles, G Morgan, J Treleaven, S Kulkarni, C Horton, R Saso, D Rolfe, G Cook & C Shaw

  2. Department of Endocrinology, Churchill Hospital, Oxford, UK

    J Wass

Authors
  1. B Sirohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Powles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Treleaven
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Kulkarni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Horton
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Saso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Rolfe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Shaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Wass
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Powles.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sirohi, B., Powles, R., Morgan, G. et al. Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study. Bone Marrow Transplant 39, 115–120 (2007). https://doi.org/10.1038/sj.bmt.1705545

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705545

Keywords

This article is cited by

Search

Advanced search

Quick links